Document is current

Article History

Received: 15 April 2024

Accepted: 1 August 2024

First Online: 13 August 2024

Declarations

:

: The trial was conducted according to the International Council for Harmonisation, Good Clinical Practice standards and the Declaration of Helsinki, and with independent ethics committee approval. Written informed consent from the patient, or legally authorised representative, was obtained in compliance with all local legal requirements.

: Not applicable.

: MSF reports grant support from BioMérieux, speaker fees from BioMérieux and Fisher & Paykel, and consultancy fees from Pfizer (all outside the submitted work); J-FT reports grant support from MSD, Pfizer and Thermo Fisher, consultancy fees from Becton Dickinson, Gilead Sciences, MSD, and Pfizer, speaker fees from MSD, Pfizer and Shionogi, and Chairmanship of the Critical Care section of the European Congress of Clinical Microbiology and Infectious Diseases; JC reports grant support from Biotest and Grifols, and consultancy fees and speaker fees from LFB; SA reports consultancy fees from AstraZeneca and Boehringer Ingelheim, speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Sandoz, and support for meeting attendance from AstraZeneca and Boehringer Ingelheim (all outside the submitted work); AT reports consultancy fees and speaker fees from Biotest AG, Janssen, MSD and Pfizer. CCH, TH, PL, IB, AS, MR, and SW are employees of Biotest AG. AW-D was an employee of Biotest AG during trial conduct and the writing of this manuscript. JS is an employee of Grifols SA, as well as an executive board member of Biotest AG, which has received a German Government Grant (Bundesministerium für Bildung und Forschung [BMBF]). AA, VCA, MR, LAH, GT, MF, IG, DP, and RP have no competing interests to declare.